ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives
DOI: https://doi.org/10.2147/JIR.S284768
IF: 4.5
2022-04-22
Journal of Inflammation Research
Abstract:Keziah Austin, 1, &ast Shalini Janagan, 2, &ast Matthew Wells, 3 Helena Crawshaw, 4 Stephen McAdoo, 5 Joanna C Robson 2, 6 1 Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, UK; 2 Department of Rheumatology, Bristol Royal Infirmary, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK; 3 Department of Rheumatology, North Bristol NHS Trust, Bristol, UK; 4 Department of Rheumatology, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK; 5 Department of Medicine, Imperial College London, London, UK; 6 Faculty of Health and Applied Sciences, University of the West of England, Bristol, UK &astThese authors contributed equally to this work Correspondence: Keziah Austin, Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, UK, Email The ANCA associated vasculitides (AAVs) affect a range of internal organs including ear nose and throat, respiratory tract, kidneys, skin and nervous system. They include granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA) and microscopic polyangiitis (MPA). The AAVs are treated with high dose glucocorticoids, immunosuppressants, and targeted biological medications. Since the 1990s classification criteria for the AAVs have been based on clinical features, laboratory tests and basic imaging; an initiative to update the classification criteria incorporating newer tests, for example, anti-neutrophil cytoplasmic antibodies (ANCA) and novel imaging techniques will be published this year. There is also evidence for classification of patients based on ANCA subtype; those with anti-proteinase 3 antibodies (PR3) or anti-myeloperoxidase antibodies (MPO) have differences in response to treatment and clinical outcomes. An update is described within this review. The pathogenesis of AAV involves necrotizing inflammation of small to medium blood vessels involving multiple immunological pathways. We present an update on emerging evidence related to auto-antibodies, complement and lymphocyte pathways. This review describes emerging treatment regimens, including evidence for plasma exchange in severe disease and the inhibitor of the complement C5a receptor (C5aR) inhibitor, Avacopan. Lastly, patient reported outcomes are key secondary outcomes in randomised controlled trials and increasingly clinical practice, we report development in disease specific and glucocorticoid-specific PROs. Keywords: vasculitis, pathogenesis, patient-reported outcomes, epidemiology The anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are a heterogenous group of rare systemic disorders comprising granulomatosis with polyangiitis (GPA, previously Wegener's granulomatosis), eosinophilic granulomatosis with polyangiitis (EGPA, previously Churg-Strauss syndrome), and microscopic polyangiitis (MPA). They are characterised by necrotising inflammation of small and medium blood vessels, pauci-immune on histopathological analysis, but associated with antibodies directed at two key antigenic targets: leukocyte proteinase 3 (PR3-ANCA) and myeloperoxidase (MPO-ANCA). Patients with GPA tend to be PR3-ANCA positive, whilst MPA patients are predominantly MPO-ANCA positive, though this is not definitive and there is not a clear overlap between ANCA subtype and clinical syndrome. Clinical features are wide-ranging and varied, but affected organ systems include the kidneys, upper and lower respiratory tracts, eyes, peripheral nerves, skin and brain. 1 Historically, AAV has been divided into subtypes depending on clinical phenotype. In 1990, the American College of Rheumatology published classification criteria for seven primary vasculitides including GPA (then known as Wegener's Granulomatosis) and EGPA (then known as Churg-Strauss syndrome). 2 The criteria were clinico-pathological, and were developed prior to the recognition of MPA as an AAV subtype, and prior to the discovery and widespread use of ANCA testing as a diagnostic tool. 3 Subsequently, the Chapel Hill Consensus Guidelines developed AAV nomenclature to include ANCA serology, 4 but with the focus remaining on traditional clinical diagnoses of GPA, EGPA and MPA. One emerging area of thought is that, given the significant overlap in clinical phenotype between these subtypes, AAV should be classified according to ANCA (PR3 vs MPO) specificity, an aspect of the disease which is increasingly recognised as of vital importance in terms of genetics, morbidity and mortality, and relapse rates. 5 This article, with a focus on both clinico-pathological and immunological AAV subtypes, will explore recent insight -Abstract Truncated-
immunology